We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- The Australian study of ageing (AIBL)
- Methodology - key outcomes
- AIBL design
- Demographics
- PIB and other ligands
- Abeta imaging
- Amyloid imaging
- 11C-PIB in the differential diagnosis of AD
- The progression of AD
- Familial AD
- Selective vulnerability
- Abeta burden quantification
- PiB- frequency distribution
- Abeta and memory
- Abeta and memory (HC)
- Abeta and memory (MCI)
- Prediction of conversion from HC to MCI/AD
- Prediction of conversion from MCI to AD
- Impact of amyloid imaging in MCI patient
- Longitudinal PiB PET follow-up (1)
- Longitudinal PiB PET follow-up (2)
- Longitudinal PiB PET 5-year follow-up
- Hippocampal volume by clinical classification
- Abeta burden and regional grey matter volume
- Linear regression of PiB PET imaging
- Baseline plasma Abeta 42 & 42/40 (AIBL cohort)
- Plasma Abeta 42 levels (PiB-PET AIBL subset)
- Correlating Abeta in blood, cognition & PiB SUVR
- Mean of ApoE levels within clinical categories
- Plasma ApoE (total) levels: AIBL study
- Plasma ApoE4 levels vs. PiB-PET: AIBL study
- Biomarker discovery
- Preclinical Alzheimer's disease
- Abeta deposition
- Abnormal protein/RNA conformations
- The AIBL study team
- Neurodegeneration research group
- Collaborators
Topics Covered
- The Australian imaging, biomarkers and lifestyle (aibl) flagship study of ageing
- Methodology: key outcomes
- Abeta and amyloid imaging
- The progression of AD
- Abeta and memory
- Prediction of conversion from HC to MCI/AD
- Impact of amyloid imaging in MCI patient selection for anti-amyloid therapeutic trials
- Longitudinal PiB PET follow-up
- Plasma Abeta 42 levels in the PiB-PET AIBL subset
- Relation between Abeta oligomers in blood cellular elements, cognition and PiB SUVR
- Plasma ApoE (total) levels: the AIBL study
- Biomarker discovery
- Abeta deposition
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Masters, C.L. (2011, October 27). Abeta toxicity 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 6, 2024, from https://doi.org/10.69645/AMUD9714.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Colin L. Masters has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.